Browse the evidence

Treatment with 1α,25-dihydroxyvitamin D3 (calcitriol) increases mitochondrial oxygen consumption rate (OCR), volume, and branching in human skeletal muscle cells by modulating the expression of fusion/fission proteins and pyruvate dehydrogenase kinases.

This research highlights that muscle mitochondrial health is specifically regulated by the active form of Vitamin D (calcitriol), not just precursor forms. For individuals with muscle weakness or myopathy, ensuring adequate Vitamin D status is critical, but the underlying mechanism involves complex genomic regulation of mitochondrial fusion and energy consumption. This does not imply that everyone needs active Vitamin D medication, but it explains why Vitamin D deficiency is linked to muscle weakness and why restoring levels can improve mitochondrial function.

Omega-3 polyunsaturated fatty acids (EPA, DHA, DPA) exert anti-inflammatory and pro-resolving effects by being metabolized into specialized pro-resolving mediators (SPMs) such as resolvins, protectins, and maresins, which actively terminate inflammation and promote tissue regeneration rather than merely suppressing immune responses.

Consuming omega-3 fatty acids (EPA, DHA, DPA) supports the body's active resolution of inflammation through specialized mediators like resolvins and protectins. This process helps clear cellular debris, promotes tissue regeneration, and regulates immune responses, offering a pathway to manage chronic inflammatory states associated with diseases like cardiovascular issues and autoimmune disorders.

Obesity (BMI > 30 kg/m2) significantly impairs female fertility by causing insulin resistance, altering adipokine profiles (high leptin, low adiponectin), and disrupting the hypothalamic-pituitary-gonadal axis, leading to ovulatory disorders and reduced spontaneous conception rates.

If you have a BMI over 30, your risk of infertility increases by 5% for every point above 29. This is driven by hormonal imbalances like insulin resistance and altered leptin levels. Weight loss is recommended to improve fertility outcomes, as it can restore hormonal balance and improve oocyte quality.

Insulin resistance in obese women directly impairs fertility by stimulating ovarian androgen synthesis and reducing sex hormone-binding globulin (SHBG), leading to hyperandrogenism and ovulatory dysfunction.

Insulin resistance doesn't just affect blood sugar; it directly tells your ovaries to produce more testosterone and reduces the protein that binds it, leaving more active testosterone to disrupt ovulation. Managing insulin sensitivity is key to restoring hormonal balance.

Pre-emptive switching from thymidine analogues (stavudine and zidovudine) is recommended to prevent lipoatrophy, as these drugs are strongly associated with subcutaneous fat loss.

If you are taking stavudine or zidovudine, discuss switching to tenofovir or abacavir with your doctor. These older drugs are linked to facial and limb fat loss (lipoatrophy). Switching can help restore some fat, though it happens slowly. Ensure your doctor checks for potential side effects like kidney issues (tenofovir) or allergic reactions (abacavir).

Statins are the first-line pharmacological therapy for lowering LDL-cholesterol in HIV patients, but require careful dose adjustment and monitoring due to drug-drug interactions with protease inhibitors (PIs) and NNRTIs.

If lifestyle changes aren't enough, statins are the first drug choice for high cholesterol. However, some statins interact dangerously with certain HIV drugs (like ritonavir-boosted PIs). Your doctor will choose a safe statin (like atorvastatin or rosuvastatin) and adjust the dose to avoid side effects while lowering your cholesterol.

Combined endurance and resistance exercise training significantly improves baroreflex sensitivity (BRS) in patients with type 2 diabetes, independent of changes in central hemodynamics.

If you have Type 2 Diabetes, engaging in a structured exercise program that includes both aerobic activity (like walking or jogging) and strength training, performed four times a week for a year, can significantly improve your body's ability to regulate blood pressure (baroreflex sensitivity). This improvement is linked to better blood sugar control rather than changes in artery stiffness. This suggests that consistent, combined exercise is a powerful tool for reducing cardiovascular risk in diabetes, even if it doesn't change the physical stiffness of your arteries.

Central obesity, measured by waist circumference (WC) or waist-to-hip ratio (WHR), is independently associated with an increased risk of nonalcoholic fatty liver disease (NAFLD), even after adjusting for general obesity (BMI).

Monitor your waist circumference, not just your weight. If your waist is large, your risk for fatty liver disease is elevated, even if your BMI is normal. Prioritize reducing abdominal fat through diet and physical activity to mitigate this risk.

General obesity, measured by BMI, is independently associated with an increased risk of NAFLD, even after adjusting for central obesity (WC).

Higher BMI is associated with a higher risk of fatty liver, even if you don't have a large waist. Maintaining a healthy weight is important for liver health.

Gut microbiota composition directly influences host glycemic control and insulin sensitivity through mechanisms including incretin secretion, short-chain fatty acid (SCFA) production, and bile acid metabolism.

Your gut bacteria play a key role in how your body handles sugar. Eating non-digestible carbohydrates (like inulin and oligofructose) can feed beneficial bacteria that produce short-chain fatty acids and stimulate hormones (GLP-1) that improve insulin response. This suggests that dietary fiber is not just for digestion but is a metabolic tool for glycemic control.

Prebiotic supplementation with non-digestible carbohydrates (e.g., oligofructose, inulin) improves glucose tolerance and insulin response by increasing GLP-1 secretion and SCFA production.

Incorporate prebiotic fibers like inulin or oligofructose into your diet. These are found in foods like chicory root, garlic, and onions, or taken as supplements. They feed gut bacteria that produce beneficial compounds (SCFAs) and stimulate hormones (GLP-1) that help lower blood sugar and reduce appetite.

Blocking myostatin/activin signaling (via ActRIIB blockade) promotes muscle hypertrophy and can reverse cancer cachexia by inhibiting SMAD2/3 signaling and stimulating SMAD1/5/8 pathways.

For those struggling with severe muscle loss, such as in cancer cachexia, therapies that block myostatin/activin signaling show promise in preserving and even increasing muscle mass. This approach targets the root cause of excessive muscle breakdown rather than just stimulating synthesis.

Consuming a high-fat lunch rich in monounsaturated fatty acids (MUFA, specifically oleic acid) stimulates appetite and increases subsequent energy intake compared to consuming lunches rich in polyunsaturated (PUFA) or saturated fatty acids (SFA).

If you are trying to control your appetite, the type of fat in your meal matters. A lunch high in monounsaturated fats (like olive oil) may leave you feeling less full and cause you to eat more later compared to a lunch high in polyunsaturated (like sunflower oil) or saturated fats (like shea butter), assuming the total fat content and calories are the same. To maximize satiety from a high-fat meal, consider using polyunsaturated fats.

In women, short sleep duration (≤5 hours) is associated with significantly higher levels of high-sensitivity C-reactive protein (hs-CRP) compared to 7 hours of sleep, whereas no such association exists in men.

If you are a woman, consistently sleeping 5 hours or less is linked to higher levels of hs-CRP, a marker of inflammation and cardiovascular risk, compared to sleeping 7 hours. This specific inflammatory risk was not observed in men in this study. Prioritizing 7-8 hours of sleep may be particularly important for managing inflammation in women.

In women, sleeping 8 hours is associated with significantly lower Interleukin-6 (IL-6) levels compared to sleeping 7 hours, suggesting an optimal sleep window for this specific inflammatory marker.

For women, extending sleep from 7 to 8 hours may help lower IL-6, a key inflammatory marker. While 7 hours is often cited as standard, this data suggests 8 hours might be the sweet spot for inflammation control in women, whereas men showed no such benefit.

Weight loss induced by diet and exercise improves insulin sensitivity in overweight and obese postmenopausal women, an effect mediated by reductions in systemic inflammation (specifically CRP, IL-6, and sTNFR-1) independent of fat mass loss.

For postmenopausal women, combining a modest caloric deficit (250-350 kcal/day) with regular moderate-intensity exercise (3x/week) significantly improves how your body uses insulin. This benefit comes not just from losing weight, but from the reduction in body-wide inflammation, which directly helps insulin work better.

In obese non-diabetic adults, experiencing transient nausea or vomiting during dose escalation of liraglutide 3.0 mg is associated with significantly greater weight loss compared to those who do not experience these symptoms.

If you are taking liraglutide for weight loss, experiencing nausea or vomiting, especially in the first few weeks, is common and often a sign that the medication is effectively engaging your GLP-1 receptors. This side effect is linked to greater weight loss. It is usually transient and mild. Do not stop the medication abruptly; instead, discuss slower dose escalation with your provider to manage symptoms while maintaining the therapeutic benefit.

Shift work involving circadian misalignment and chronic sleep restriction significantly increases the risk of cardiovascular events, metabolic syndrome, and mood disorders.

If you work nights or rotating shifts, recognize that your body's internal clock is fighting against your schedule. This misalignment directly increases your risk for heart disease, diabetes, and mood disorders. Prioritize sleep quality, manage stress, and be aware of your cardiovascular risk factors more closely than day workers.

Timed exposure to bright light during night shifts and melatonin administration can facilitate circadian adaptation and improve sleep quality in shift workers.

To adapt to night shifts, expose yourself to bright light during your shift and in the early morning. After your shift, wear sunglasses to block morning light to help your body adjust. You can also take melatonin (1-2 mg) to help you sleep during the day. Avoid rapidly rotating schedules if possible.

Androgenic-anabolic steroid administration significantly lowers serum Lipoprotein(a) [Lp(a)] concentrations, which may have a beneficial effect on cardiovascular risk, although this benefit is offset by the adverse effects on other lipids.

AAS use tends to lower Lipoprotein(a), which is generally considered a good thing for heart health. However, because AAS simultaneously destroys your 'good' cholesterol (HDL) and raises 'bad' markers, you cannot assume the Lp(a) benefit cancels out the damage. The net effect on heart disease risk is likely negative and complex.

Recovery of adverse lipid profiles (HDL, Apo-A1, Lp(a)) after stopping AAS use is prolonged and depends on the duration of prior AAS use, with 14 weeks of use leading to slower normalization than 8 weeks.

If you stop using AAS, your cholesterol levels do not immediately return to normal. If you used steroids for 14 weeks, your 'bad' cholesterol markers may remain elevated for months, keeping your cardiovascular risk high long after you stop injecting.

n-3 LC-PUFA reduce liver steatosis and hepatic glucose output by activating PPAR-alpha to stimulate fatty acid oxidation and suppressing SREBP-1c to inhibit lipogenesis enzymes.

For individuals with fatty liver, n-3 fatty acids may help reduce liver fat by shifting the liver's metabolism to burn fat (via PPAR-alpha) and stop making new fat (via SREBP-1c suppression).

Incretin stimulation via GLP-1 receptor agonists (e.g., liraglutide, exenatide) and DPP-4 inhibitors reduces visceral and epicardial adipose tissue volume and thickness while promoting the browning of white adipocytes, thereby alleviating insulin resistance and associated cardiovascular pathologies in obese and type-2 diabetic patients.

For patients with obesity and Type-2 Diabetes, GLP-1 receptor agonists (like liraglutide) and DPP-4 inhibitors are effective pharmacological tools to specifically target dangerous visceral and epicardial fat. Unlike Metformin, these drugs significantly shrink epicardial fat thickness, which is linked to cardiovascular risk. This reduction in fat volume, combined with improved insulin sensitivity, offers a targeted approach to preventing heart disease in this population.

Bariatric surgeries, specifically Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG), reduce fasting plasma LEAP2 levels in humans with obesity, correlating with weight loss and improved metabolic markers.

Bariatric surgeries like RYGB and VSG lower levels of the hormone LEAP2, which is typically high in obesity. This hormonal shift, along with weight loss, may help maintain the weight loss by altering hunger signaling. This suggests that surgery works partly by resetting hormonal balances.